Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|JAK2 R938Q||childhood B-cell acute lymphoblastic leukemia||resistant||JAK2 Inhibitor - ATP competitive||Ruxolitinib||Preclinical - Patient cell culture||Actionable||In a preclinical study, bone marrow mononuclear cells from a pediatric B-cell acute lymphoblastic leukemia with an acquired Jak2 R938Q mutation were resistant to Jakafi (ruxolitinib) (PMID: 29025600).||29025600|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|